Eluminex Biosciences Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 65

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $9.2M

  • Investors
  • 11

Eluminex Biosciences General Information

Description

Manufacturer of ophthalmic therapeutics designed to treat vision-threatening retinal and ocular diseases. The company develops protein- and antibody-based drugs targeting conditions such as wet age-related macular degeneration, diabetic macular edema, and retinal vascular disorders, enabling healthcare providers to address unmet needs in ophthalmology through innovative treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 401, Building B7, Suzhou Biomedical Industrial Park
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Unit 401, Building B7, Suzhou Biomedical Industrial Park
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 0512

Eluminex Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eluminex Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B1) 20-Aug-2023 $9.2M Completed Generating Revenue
2. Early Stage VC (Series B) 14-Feb-2023 Completed Generating Revenue
1. Early Stage VC (Series A) 20-Nov-2020 $50M $50M Completed Generating Revenue
To view Eluminex Biosciences’s complete valuation and funding history, request access »

Eluminex Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eluminex Biosciences Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Oriza FOFs Fund of Funds Minority
Suzhou Guofa Venture Capital Venture Capital Minority
Suzhou Trust Limited Partner Minority
3E Bioventures (China) Venture Capital Minority
Beijing Jiurui Tiancheng Technology Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Eluminex Biosciences Acquisitions (1)

Eluminex Biosciences’s most recent deal was a Merger/Acquisition with Retinagenix Holdings. The deal was made on 19-Jan-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Retinagenix Holdings 19-Jan-2022 Merger/Acquisition Drug Discovery
To view Eluminex Biosciences’s complete acquisitions history, request access »

Eluminex Biosciences FAQs

  • When was Eluminex Biosciences founded?

    Eluminex Biosciences was founded in 2020.

  • Where is Eluminex Biosciences headquartered?

    Eluminex Biosciences is headquartered in Suzhou, China.

  • What is the size of Eluminex Biosciences?

    Eluminex Biosciences has 65 total employees.

  • What industry is Eluminex Biosciences in?

    Eluminex Biosciences’s primary industry is Drug Discovery.

  • Is Eluminex Biosciences a private or public company?

    Eluminex Biosciences is a Private company.

  • What is Eluminex Biosciences’s current revenue?

    The current revenue for Eluminex Biosciences is .

  • How much funding has Eluminex Biosciences raised over time?

    Eluminex Biosciences has raised $100M.

  • Who are Eluminex Biosciences’s investors?

    Oriza FOFs, Suzhou Guofa Venture Capital, Suzhou Trust, 3E Bioventures (China), and Beijing Jiurui Tiancheng Technology are 5 of 11 investors who have invested in Eluminex Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process